

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C12Q 1/68, C07K 14/705		A3	(11) International Publication Number: WO 97/09348
			(43) International Publication Date: 13 March 1997 (13.03.97)
(21) International Application Number: PCT/EP96/03933		(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 9 September 1996 (09.09.96)			
(30) Priority Data:		Published	
9518272.1	8 September 1995 (08.09.95) GB	With international search report.	
9605550.4	15 March 1996 (15.03.96) GB	Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
9607532.0	11 April 1996 (11.04.96) GB		
9609576.5	8 May 1996 (08.05.96) GB		
(71) Applicant (for all designated States except US): KARO BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE).		(88) Date of publication of the international search report: 24 April 1997 (24.04.97)	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): KUIPER, George, G., J., M. [SE/SE]; Center for Biotechnology and Department of Medical Nutrition, Karolinska Institute, Novum, S-141 86 Huddinge (SE). ENMARK, Eva [SE/SE]; Center for Biotechnology and Department of Medical Nutrition, Karolinska Institute, Novum, S-141 86 Huddinge (SE). GUSTAFSSON, Jan-Ake [SE/SE]; Center for Biotechnology and Department of Medical Nutrition, Karolinska Institute, Novum, S-141 86 Huddinge (SE).			
(74) Agent: DEAN, John, Paul; Withers & Rogers, 4 Dyer's Buildings, Holborn, London EC1N 2JT (GB).			
(54) Title: ORPHAN RECEPTOR			
(57) Abstract			
<p>This invention relates to a novel estrogen receptor-related nuclear receptor, hereinafter termed "ERβ" having the amino acid sequence of Figs. 1, 13A or 14A or substantially the same amino acid sequence as the amino acid sequence shown in Figs. 1, 13A or 13B or an amino acid sequence functionally similar to that sequence. The invention also relates to DNA sequences encoding the receptor. The receptor may be useful in isolating molecules for the treatment of disorders such as prostate cancer, benign prostatic hyperplasia, osteoporosis or cardiovascular disorders and in the testing of substances for estrogenic and other hormonal effects.</p>			
<pre> graph LR ratGR[rat GR] --- Node1 Node1 --- Node2 Node1 --- Node3 Node2 --- Node4 Node2 --- Node5 Node4 --- Node6 Node4 --- Node7 Node6 --- Node8 Node6 --- Node9 Node8 --- Node10 Node8 --- Node11 Node10 --- Node12 Node10 --- Node13 Node12 --- Node14 Node12 --- Node15 Node14 --- Node16 Node14 --- Node17 Node16 --- Node18 Node16 --- Node19 Node18 --- Node20 Node18 --- Node21 Node20 --- Node22 Node20 --- Node23 Node22 --- Node24 Node22 --- Node25 Node24 --- Node26 Node24 --- Node27 Node26 --- Node28 Node26 --- Node29 Node28 --- Node30 Node28 --- Node31 Node30 --- Node32 Node30 --- Node33 Node32 --- Node34 Node32 --- Node35 Node34 --- Node36 Node34 --- Node37 Node36 --- Node38 Node36 --- Node39 Node38 --- Node40 Node38 --- Node41 Node40 --- Node42 Node40 --- Node43 Node42 --- Node44 Node42 --- Node45 Node44 --- Node46 Node44 --- Node47 Node46 --- Node48 Node46 --- Node49 Node48 --- Node50 Node48 --- Node51 Node50 --- Node52 Node50 --- Node53 Node52 --- Node54 Node52 --- Node55 Node54 --- Node56 Node54 --- Node57 Node56 --- Node58 Node56 --- Node59 Node58 --- Node60 Node58 --- Node61 Node60 --- Node62 Node60 --- Node63 Node62 --- Node64 Node62 --- Node65 Node64 --- Node66 Node64 --- Node67 Node66 --- Node68 Node66 --- Node69 Node68 --- Node70 Node68 --- Node71 Node70 --- Node72 Node70 --- Node73 Node72 --- Node74 Node72 --- Node75 Node74 --- Node76 Node74 --- Node77 Node76 --- Node78 Node76 --- Node79 Node78 --- Node80 Node78 --- Node81 Node80 --- Node82 Node80 --- Node83 Node82 --- Node84 Node82 --- Node85 Node84 --- Node86 Node84 --- Node87 Node86 --- Node88 Node86 --- Node89 Node88 --- Node90 Node88 --- Node91 Node90 --- Node92 Node90 --- Node93 Node92 --- Node94 Node92 --- Node95 Node94 --- Node96 Node94 --- Node97 Node96 --- Node98 Node96 --- Node99 Node98 --- Node100 Node98 --- Node101 Node100 --- Node102 Node100 --- Node103 Node102 --- Node104 Node102 --- Node105 Node104 --- Node106 Node104 --- Node107 Node106 --- Node108 Node106 --- Node109 Node108 --- Node110 Node108 --- Node111 Node110 --- Node112 Node110 --- Node113 Node112 --- Node114 Node112 --- Node115 Node114 --- Node116 Node114 --- Node117 Node116 --- Node118 Node116 --- Node119 Node118 --- Node120 Node118 --- Node121 Node120 --- Node122 Node120 --- Node123 Node122 --- Node124 Node122 --- Node125 Node124 --- Node126 Node124 --- Node127 Node126 --- Node128 Node126 --- Node129 Node128 --- Node130 Node128 --- Node131 Node130 --- Node132 Node130 --- Node133 Node132 --- Node134 Node132 --- Node135 Node134 --- Node136 Node134 --- Node137 Node136 --- Node138 Node136 --- Node139 Node138 --- Node140 Node138 --- Node141 Node140 --- Node142 Node140 --- Node143 Node142 --- Node144 Node142 --- Node145 Node144 --- Node146 Node144 --- Node147 Node146 --- Node148 Node146 --- Node149 Node148 --- Node150 Node148 --- Node151 Node150 --- Node152 Node150 --- Node153 Node152 --- Node154 Node152 --- Node155 Node154 --- Node156 Node154 --- Node157 Node156 --- Node158 Node156 --- Node159 Node158 --- Node160 Node158 --- Node161 Node160 --- Node162 Node160 --- Node163 Node162 --- Node164 Node162 --- Node165 Node164 --- Node166 Node164 --- Node167 Node166 --- Node168 Node166 --- Node169 Node168 --- Node170 Node168 --- Node171 Node170 --- Node172 Node170 --- Node173 Node172 --- Node174 Node172 --- Node175 Node174 --- Node176 Node174 --- Node177 Node176 --- Node178 Node176 --- Node179 Node178 --- Node180 Node178 --- Node181 Node180 --- Node182 Node180 --- Node183 Node182 --- Node184 Node182 --- Node185 Node184 --- Node186 Node184 --- Node187 Node186 --- Node188 Node186 --- Node189 Node188 --- Node190 Node188 --- Node191 Node190 --- Node192 Node190 --- Node193 Node192 --- Node194 Node192 --- Node195 Node194 --- Node196 Node194 --- Node197 Node196 --- Node198 Node196 --- Node199 Node198 --- Node200 Node198 --- Node201 Node200 --- Node202 Node200 --- Node203 Node202 --- Node204 Node202 --- Node205 Node204 --- Node206 Node204 --- Node207 Node206 --- Node208 Node206 --- Node209 Node208 --- Node210 Node208 --- Node211 Node210 --- Node212 Node210 --- Node213 Node212 --- Node214 Node212 --- Node215 Node214 --- Node216 Node214 --- Node217 Node216 --- Node218 Node216 --- Node219 Node218 --- Node220 Node218 --- Node221 Node220 --- Node222 Node220 --- Node223 Node222 --- Node224 Node222 --- Node225 Node224 --- Node226 Node224 --- Node227 Node226 --- Node228 Node226 --- Node229 Node228 --- Node230 Node228 --- Node231 Node230 --- Node232 Node230 --- Node233 Node232 --- Node234 Node232 --- Node235 Node234 --- Node236 Node234 --- Node237 Node236 --- Node238 Node236 --- Node239 Node238 --- Node240 Node238 --- Node241 Node240 --- Node242 Node240 --- Node243 Node242 --- Node244 Node242 --- Node245 Node244 --- Node246 Node244 --- Node247 Node246 --- Node248 Node246 --- Node249 Node248 --- Node250 Node248 --- Node251 Node250 --- Node252 Node250 --- Node253 Node252 --- Node254 Node252 --- Node255 Node254 --- Node256 Node254 --- Node257 Node256 --- Node258 Node256 --- Node259 Node258 --- Node260 Node258 --- Node261 Node260 --- Node262 Node260 --- Node263 Node262 --- Node264 Node262 --- Node265 Node264 --- Node266 Node264 --- Node267 Node266 --- Node268 Node266 --- Node269 Node268 --- Node270 Node268 --- Node271 Node270 --- Node272 Node270 --- Node273 Node272 --- Node274 Node272 --- Node275 Node274 --- Node276 Node274 --- Node277 Node276 --- Node278 Node276 --- Node279 Node278 --- Node280 Node278 --- Node281 Node280 --- Node282 Node280 --- Node283 Node282 --- Node284 Node282 --- Node285 Node284 --- Node286 Node284 --- Node287 Node286 --- Node288 Node286 --- Node289 Node288 --- Node290 Node288 --- Node291 Node290 --- Node292 Node290 --- Node293 Node292 --- Node294 Node292 --- Node295 Node294 --- Node296 Node294 --- Node297 Node296 --- Node298 Node296 --- Node299 Node298 --- Node300 Node298 --- Node301 Node300 --- Node302 Node300 --- Node303 Node302 --- Node304 Node302 --- Node305 Node304 --- Node306 Node304 --- Node307 Node306 --- Node308 Node306 --- Node309 Node308 --- Node310 Node308 --- Node311 Node310 --- Node312 Node310 --- Node313 Node312 --- Node314 Node312 --- Node315 Node314 --- Node316 Node314 --- Node317 Node316 --- Node318 Node316 --- Node319 Node318 --- Node320 Node318 --- Node321 Node320 --- Node322 Node320 --- Node323 Node322 --- Node324 Node322 --- Node325 Node324 --- Node326 Node324 --- Node327 Node326 --- Node328 Node326 --- Node329 Node328 --- Node330 Node328 --- Node331 Node330 --- Node332 Node330 --- Node333 Node332 --- Node334 Node332 --- Node335 Node334 --- Node336 Node334 --- Node337 Node336 --- Node338 Node336 --- Node339 Node338 --- Node340 Node338 --- Node341 Node340 --- Node342 Node340 --- Node343 Node342 --- Node344 Node342 --- Node345 Node344 --- Node346 Node344 --- Node347 Node346 --- Node348 Node346 --- Node349 Node348 --- Node350 Node348 --- Node351 Node350 --- Node352 Node350 --- Node353 Node352 --- Node354 Node352 --- Node355 Node354 --- Node356 Node354 --- Node357 Node356 --- Node358 Node356 --- Node359 Node358 --- Node360 Node358 --- Node361 Node360 --- Node362 Node360 --- Node363 Node362 --- Node364 Node362 --- Node365 Node364 --- Node366 Node364 --- Node367 Node366 --- Node368 Node366 --- Node369 Node368 --- Node370 Node368 --- Node371 Node370 --- Node372 Node370 --- Node373 Node372 --- Node374 Node372 --- Node375 Node374 --- Node376 Node374 --- Node377 Node376 --- Node378 Node376 --- Node379 Node378 --- Node380 Node378 --- Node381 Node380 --- Node382 Node380 --- Node383 Node382 --- Node384 Node382 --- Node385 Node384 --- Node386 Node384 --- Node387 Node386 --- Node388 Node386 --- Node389 Node388 --- Node390 Node388 --- Node391 Node390 --- Node392 Node390 --- Node393 Node392 --- Node394 Node392 --- Node395 Node394 --- Node396 Node394 --- Node397 Node396 --- Node398 Node396 --- Node399 Node398 --- Node400 Node398 --- Node401 Node400 --- Node402 Node400 --- Node403 Node402 --- Node404 Node402 --- Node405 Node404 --- Node406 Node404 --- Node407 Node406 --- Node408 Node406 --- Node409 Node408 --- Node410 Node408 --- Node411 Node410 --- Node412 Node410 --- Node413 Node412 --- Node414 Node412 --- Node415 Node414 --- Node416 Node414 --- Node417 Node416 --- Node418 Node416 --- Node419 Node418 --- Node420 Node418 --- Node421 Node420 --- Node422 Node420 --- Node423 Node422 --- Node424 Node422 --- Node425 Node424 --- Node426 Node424 --- Node427 Node426 --- Node428 Node426 --- Node429 Node428 --- Node430 Node428 --- Node431 Node430 --- Node432 Node430 --- Node433 Node432 --- Node434 Node432 --- Node435 Node434 --- Node436 Node434 --- Node437 Node436 --- Node438 Node436 --- Node439 Node438 --- Node440 Node438 --- Node441 Node440 --- Node442 Node440 --- Node443 Node442 --- Node444 Node442 --- Node445 Node444 --- Node446 Node444 --- Node447 Node446 --- Node448 Node446 --- Node449 Node448 --- Node450 Node448 --- Node451 Node450 --- Node452 Node450 --- Node453 Node452 --- Node454 Node452 --- Node455 Node454 --- Node456 Node454 --- Node457 Node456 --- Node458 Node456 --- Node459 Node458 --- Node460 Node458 --- Node461 Node460 --- Node462 Node460 --- Node463 Node462 --- Node464 Node462 --- Node465 Node464 --- Node466 Node464 --- Node467 Node466 --- Node468 Node466 --- Node469 Node468 --- Node470 Node468 --- Node471 Node470 --- Node472 Node470 --- Node473 Node472 --- Node474 Node472 --- Node475 Node474 --- Node476 Node474 --- Node477 Node476 --- Node478 Node476 --- Node479 Node478 --- Node480 Node478 --- Node481 Node480 --- Node482 Node480 --- Node483 Node482 --- Node484 Node482 --- Node485 Node484 --- Node486 Node484 --- Node487 Node486 --- Node488 Node486 --- Node489 Node488 --- Node490 Node488 --- Node491 Node490 --- Node492 Node490 --- Node493 Node492 --- Node494 Node492 --- Node495 Node494 --- Node496 Node494 --- Node497 Node496 --- Node498 Node496 --- Node499 Node498 --- Node500 Node498 --- Node501 Node500 --- Node502 Node500 --- Node503 Node502 --- Node504 Node502 --- Node505 Node504 --- Node506 Node504 --- Node507 Node506 --- Node508 Node506 --- Node509 Node508 --- Node510 Node508 --- Node511 Node510 --- Node512 Node510 --- Node513 Node512 --- Node514 Node512 --- Node515 Node514 --- Node516 Node514 --- Node517 Node516 --- Node518 Node516 --- Node519 Node518 --- Node520 Node518 --- Node521 Node520 --- Node522 Node520 --- Node523 Node522 --- Node524 Node522 --- Node525 Node524 --- Node526 Node524 --- Node527 Node526 --- Node528 Node526 --- Node529 Node528 --- Node530 Node528 --- Node531 Node530 --- Node532 Node530 --- Node533 Node532 --- Node534 Node532 --- Node535 Node534 --- Node536 Node534 --- Node537 Node536 --- Node538 Node536 --- Node539 Node538 --- Node540 Node538 --- Node541 Node540 --- Node542 Node540 --- Node543 Node542 --- Node544 Node542 --- Node545 Node544 --- Node546 Node544 --- Node547 Node546 --- Node548 Node546 --- Node549 Node548 --- Node550 Node548 --- Node551 Node550 --- Node552 Node550 --- Node553 Node552 --- Node554 Node552 --- Node555 Node554 --- Node556 Node554 --- Node557 Node556 --- Node558 Node556 --- Node559 Node558 --- Node560 Node558 --- Node561 Node560 --- Node562 Node560 --- Node563 Node562 --- Node564 Node562 --- Node565 Node564 --- Node566 Node564 --- Node567 Node566 --- Node568 Node566 --- Node569 Node568 --- Node570 Node568 --- Node571 Node570 --- Node572 Node570 --- Node573 Node572 --- Node574 Node572 --- Node575 Node574 --- Node576 Node574 --- Node577 Node576 --- Node578 Node576 --- Node579 Node578 --- Node580 Node578 --- Node581 Node580 --- Node582 Node580 --- Node583 Node582 --- Node584 Node582 --- Node585 Node584 --- Node586 Node584 --- Node587 Node586 --- Node588 Node586 --- Node589 Node588 --- Node590 Node588 --- Node591 Node590 --- Node592 Node590 --- Node593 Node592 --- Node594 Node592 --- Node595 Node594 --- Node596 Node594 --- Node597 Node596 --- Node598 Node596 --- Node599 Node598 --- Node600 Node598 --- Node601 Node600 --- Node602 Node600 --- Node603 Node602 --- Node604 Node602 --- Node605 Node604 --- Node606 Node604 --- Node607 Node606 --- Node608 Node606 --- Node609 Node608 --- Node610 Node608 --- Node611 Node610 --- Node612 Node610 --- Node613 Node612 --- Node614 Node612 --- Node615 Node614 --- Node616 Node614 --- Node617 Node616 --- Node618 Node616 --- Node619 Node618 --- Node620 Node618 --- Node621 Node620 --- Node622 Node620 --- Node623 Node622 --- Node624 Node622 --- Node625 Node624 --- Node626 Node624 --- Node627 Node626 --- Node628 Node626 --- Node629 Node628 --- Node630 Node628 --- Node631 Node630 --- Node632 Node630 --- Node633 Node632 --- Node634 Node632 --- Node635 Node634 --- Node636 Node634 --- Node637 Node636 --- Node638 Node636 --- Node639 Node638 --- Node640 Node638 --- Node641 Node640 --- Node642 Node640 --- Node643 Node642 --- Node644 Node642 --- Node645 Node644 --- Node646 Node644 --- Node647 Node646 --- Node648 Node646 --- Node649 Node648 --- Node650 Node648 --- Node651 Node650 --- Node652 Node650 --- Node653 Node652 --- Node654 Node652 --- Node655 Node654 --- Node656 Node654 --- Node657 Node656 --- Node658 Node656 --- Node659 Node658 --- Node660 Node658 --- Node661 Node660 --- Node662 Node660 --- Node663 Node662 --- Node664 Node662 --- Node665 Node664 --- Node666 Node664 --- Node667 Node666 --- Node668 Node666 --- Node669 Node668 --- Node670 Node668 --- Node671 Node670 --- Node672 Node670 --- Node673 Node672 --- Node674 Node672 --- Node675 Node674 --- Node676 Node674 --- Node677 Node676 --- Node678 Node676 --- Node679 Node678 --- Node680 Node678 --- Node681 Node680 --- Node682 Node680 --- Node683 Node682 --- Node684 Node682 --- Node685 Node684 --- Node686 Node684 --- Node687 Node686 --- Node688 Node686 --- Node689 Node688 --- Node690 Node688 --- Node691 Node690 --- Node692 Node690 --- Node693 Node692 --- Node694 Node692 --- Node695 Node694 --- Node696 Node694 --- Node697 Node696 --- Node698 Node696 --- Node699 Node698 --- Node700 Node698 --- Node701 Node700 --- Node702 Node700 --- Node703 Node702 --- Node704 Node702 --- Node705 Node704 --- Node706 Node704 --- Node707 Node706 --- Node708 Node706 --- Node709 Node708 --- Node710 Node708 --- Node711 Node710 --- Node712 Node710 --- Node713 Node712 --- Node714 Node712 --- Node715 Node714 --- Node716 Node714 --- Node717 Node716 --- Node718 Node716 --- Node719 Node718 --- Node720 Node718 --- Node721 Node720 --- Node722 Node720 --- Node723 Node722 --- Node724 Node722 --- Node725 Node724 --- Node726 Node724 --- Node727 Node726 --- Node728 Node726 --- Node729 Node728 --- Node730 Node728 --- Node731 Node730 --- Node732 Node730 --- Node733 Node732 --- Node734 Node732 --- Node735 Node734 --- Node736 Node734 --- Node737 Node736 --- Node738 Node736 --- Node739 Node738 --- Node740 Node738 --- Node741 Node740 --- Node742 Node740 --- Node743 Node742 --- Node744 Node742 --- Node745 Node744 --- Node746 Node744 --- Node747 Node746 --- Node748 Node746 --- Node749 Node748 --- Node750 Node748 --- Node751 Node750 --- Node752 Node750 --- Node753 Node752 --- Node754 Node752 --- Node755 Node754 --- Node756 Node754 --- Node757 Node756 --- Node758 Node756 --- Node759 Node758 --- Node760 Node758 --- Node761 Node760 --- Node762 Node760 --- Node763 Node762 --- Node764 Node762 --- Node765 Node764 --- Node766 Node764 --- Node767 Node766 --- Node768 Node766 --- Node769 Node768 --- Node770 Node768 --- Node771 Node770 --- Node772 Node770 --- Node773 Node772 --- Node774 Node772 --- Node775 Node774 --- Node776 Node774 --- Node777 Node776 --- Node778 Node776 --- Node779 Node778 --- Node780 Node778 --- Node781 Node780 --- Node782 Node780 --- Node783 Node782 --- Node784 Node782 --- Node785 Node784 --- Node786 Node784 --- Node787 Node786 --- Node788 Node786 --- Node789 Node788 --- Node790 Node788 --- Node791 Node790 --- Node792 Node790 --- Node793 Node792 --- Node794 Node792 --- Node795 Node794 --- Node796 Node794 --- Node797 Node796 --- Node798 Node796 --- Node799 Node798 --- Node800 Node798 --- Node801 Node800 --- Node802 Node800 --- Node803 Node802 --- Node804 Node802 --- Node805 Node804 --- Node806 Node804 --- Node807 Node806 --- Node808 Node806 --- Node809 Node808 --- Node810 Node808 --- Node811 Node810 --- Node812 Node810 --- Node813 Node812 --- Node814 Node812 --- Node815 Node814 --- Node816 Node814 --- Node817 Node816 --- Node818 Node816 --- Node819 Node818 --- Node820 Node818 --- Node821 Node820 --- Node822 Node820 --- Node823 Node822 --- Node824 Node822 --- Node825 Node824 --- Node826 Node824 --- Node827 Node826 --- Node828 Node826 --- Node829 Node828 --- Node830 Node828 --- Node831 Node830 --- Node832 Node830 --- Node833 Node832 --- Node834 Node832 --- Node835 Node834 --- Node836 Node834 --- Node837 Node836 --- Node838 Node836 --- Node839 Node838 --- Node840 Node838 --- Node841 Node840 --- Node842 Node840 --- Node843 Node842 --- Node844 Node842 --- Node845 Node844 --- Node846 Node844 --- Node847 Node846 --- Node848 Node846 --- Node849 Node848 --- Node850 Node848 --- Node851 Node850 --- Node852 Node850 --- Node853 Node852 --- Node854 Node852 --- Node855 Node854 --- Node856 Node854 --- Node857 Node856 --- Node858 Node856 --- Node859 Node858 --- Node860 Node858 --- Node861 Node860 --- Node862 Node860 --- Node863 Node862 --- Node864 Node862 --- Node865 Node864 --- Node866 Node864 --- Node867 Node866 --- Node868 Node866 --- Node869 Node868 --- Node870 Node868 --- Node871 Node870 --- Node872 Node870 --- Node873 Node872 --- Node874 Node872 --- Node875 Node874 --- Node876 Node874 --- Node877 Node876 --- Node878 Node876 --- Node879 Node878 --- Node880 Node878 --- Node881 Node880 --- Node882 Node880 --- Node883 Node882 --- Node884 Node882 --- Node885 Node884 --- Node886 Node884 --- Node887 Node886 --- Node888 Node886 --- Node889 Node888 --- Node890 Node888 --- Node891 Node890 --- Node892 Node890 --- Node893 Node892 --- Node894 Node892 --- Node895 Node894 --- Node896 Node894 --- Node897 Node896 --- Node898 Node896 --- Node899 Node898 --- Node900 Node898 --- Node901 Node900 --- Node902 Node900 --- Node903 Node902 --- Node904 Node902 --- Node905 Node904 --- Node906 Node904 --- Node907 Node906 --- Node908 Node906 --- Node909 Node908 --- Node910 Node908 --- Node911 Node910 --- Node912 Node910 --- Node913 Node912 --- Node914 Node912 --- Node915 Node914 --- Node916 Node914 --- Node917 Node916 --- Node918 Node916 --- Node919 Node918 --- Node920 Node918 --- Node921 Node920 --- Node922 Node920 --- Node923 Node922 --- Node924 Node922 --- Node925 Node924 --- Node926 Node924 --- Node927 Node926 --- Node928 Node926 --- Node929 Node928 --- Node930 Node928 --- Node931 Node930 --- Node932 Node930 --- Node933 Node932 --- Node934 Node932 --- Node935 Node934 --- Node936 Node934 --- Node937 Node936 --- Node938 Node936 --- Node939 Node938 --- Node940 Node938 --- Node941 Node940 --- Node942 Node940 --- Node943 Node942 --- Node944 Node942 --- Node945 Node944 --- Node946 Node944 --- Node947 Node946 --- Node948 Node946 --- Node949 Node948 --- Node950 Node948 --- Node951 Node950 --- Node952 Node950 --- Node953 Node952 --- Node954 Node952 --- Node955 Node954 --- Node956 Node954 --- Node957 Node956 --- Node958 Node956 --- Node959 Node958 --- Node960 Node958 --- Node961 Node960 --- Node962 Node960 --- Node963 Node962 --- Node964 Node962 --- Node965 Node964 --- Node966 Node964 --- Node967 Node966 --- Node968 Node966 --- Node969 Node968 --- Node970 Node968 --- Node971 Node970 --- Node972 Node970 --- Node973 Node972 --- Node974 Node972 --- Node975 Node974 --- Node976 Node974 --- Node977 Node976 --- Node978 Node976 --- Node979 Node978 --- Node980 Node978 --- Node981 Node980 --- Node982 Node980 --- Node983 Node982 --- Node984 Node982 --- Node985 Node984 --- Node986 Node984 --- Node987 Node986 --- Node988 Node986 --- Node989 Node988 --- Node990 Node988 --- Node991 Node990 --- Node992 Node990 --- Node993 Node992 --- Node994 Node992 --- Node995 Node994 --- Node996 Node994 --- Node997 Node996 --- Node998 Node996 --- Node999 Node998 --- Node1000 Node998 --- Node1001 Node1000 --- Node1002 Node1000 --- Node1003 Node1002 --- Node1004 Node1002 --- Node1005 Node1004 --- Node1006 Node1004 --- Node1007 Node1006 --- Node1008 Node</pre>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/03933

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C12Q1/68 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NUCLEIC ACIDS RESEARCH, vol. 15, no. 6, 25 March 1987, pages 2499-2513, XP002026307 KOIKE, S. ET AL.: "Molecular cloning and characterization of a rat estrogen receptor cDNA" see the whole document ---	1,3-6,8, 9,12
X	SCIENCE, vol. 231, no. 4742, 7 March 1986, pages 1150-1154, XP000611679 GREENE G L ET AL: "SEQUENCE AND EXPRESSION OF HUMAN ESTROGEN RECEPTOR COMPLEMENTARY DNA" see the whole document --- -/--	1,3-6,8, 9,12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

27 February 1997

Date of mailing of the international search report

10.03.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fac. (+ 31-70) 340-3016

Authorized officer

Kania, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/03933

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NUCLEIC ACIDS RESEARCH, vol. 17, no. 14, 25 July 1989, pages 5477-5488, XP002026308 LEES J. ET AL.: "Identification of two transactivation domains in the mouse oestrogen receptor" see the whole document ---	1,4-6,8, 9,12
P,X	PNAS U.S.A., vol. 93, no. 12, 11 June 1996, pages 5925-5930, XP002026309 KUIPER G. ET AL.: "Cloning of a novel estrogen receptor expressed in rat prostate and ovary" see the whole document ---	1-10,12
P,X	FEBS LETTERS, vol. 392, no. 1, 19 August 1996, pages 49-53, XP002026310 MOSELMAN, S. ET AL.: "ERbeta: identification and characterization of a novel human estrogen receptor" see the whole document ---	1-12
T	MOLECULAR ENDOCRINOLOGY, vol. 10, no. 11, November 1996, pages 1293-1307, XP000645166 ENMARK E. AND GUSTAFSSON J.: "Orphan nuclear receptors- the first eight years" see the whole document -----	1-12

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/705		A2	(11) International Publication Number: WO 97/09348										
			(43) International Publication Date: 13 March 1997 (13.03.97)										
(21) International Application Number: PCT/EP96/03933		(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).											
(22) International Filing Date: 9 September 1996 (09.09.96)		<p>Published</p> <p><i>Without international search report and to be republished upon receipt of that report.</i></p>											
<p>(30) Priority Data:</p> <table border="0"> <tr> <td>9518272.1</td> <td>8 September 1995 (08.09.95)</td> <td>GB</td> </tr> <tr> <td>9605550.4</td> <td>15 March 1996 (15.03.96)</td> <td>GB</td> </tr> <tr> <td>9607532.0</td> <td>11 April 1996 (11.04.96)</td> <td>GB</td> </tr> <tr> <td>9609576.5</td> <td>8 May 1996 (08.05.96)</td> <td>GB</td> </tr> </table>				9518272.1	8 September 1995 (08.09.95)	GB	9605550.4	15 March 1996 (15.03.96)	GB	9607532.0	11 April 1996 (11.04.96)	GB	9609576.5
9518272.1	8 September 1995 (08.09.95)	GB											
9605550.4	15 March 1996 (15.03.96)	GB											
9607532.0	11 April 1996 (11.04.96)	GB											
9609576.5	8 May 1996 (08.05.96)	GB											
<p>(71) Applicant (for all designated States except US): KARO BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE).</p>													
<p>(72) Inventors; and</p>													
<p>(75) Inventors/Applicants (for US only): KUIPER, George, G., J., M. [SE/SE]; Center for Biotechnology and Department of Medical Nutrition, Karolinska Institute, Novum, S-141 86 Huddinge (SE). ENMARK, Eva [SE/SE]; Center for Biotechnology and Department of Medical Nutrition, Karolinska Institute, Novum, S-141 86 Huddinge (SE). GUSTAFSSON, Jan-Ake [SE/SE]; Center for Biotechnology and Department of Medical Nutrition, Karolinska Institute, Novum, S-141 86 Huddinge (SE).</p>													
<p>(74) Agent: DEAN, John, Paul; Withers & Rogers, 4 Dyer's Buildings, Holborn, London EC1N 2JT (GB).</p>													
<p>(54) Title: ORPHAN RECEPTOR</p>													
<p>(57) Abstract</p> <p>This invention relates to a novel estrogen receptor-related nuclear receptor, hereinafter termed "ERβ" having the amino acid sequence of Figs. 1, 13A or 14A or substantially the same amino acid sequence as the amino acid sequence shown in Figs. 1, 13A or 13B or an amino acid sequence functionally similar to that sequence. The invention also relates to DNA sequences encoding the receptor. The receptor may be useful in isolating molecules for the treatment of disorders such as prostate cancer, benign prostatic hyperplasia, osteoporosis or cardiovascular disorders and in the testing of substances for estrogenic and other hormonal effects.</p>													

JC564 U.S. PTO
09/541583
04/03/00

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

ORPHAN RECEPTOR

This invention relates to cellular nuclear receptors and their uses..

A large family of nuclear receptors which confer cells with responsiveness to molecules such as retinoid acid, vitamin D, steroid hormones and thyroid hormones has been identified. Extensive studies have shown that the members of this superfamily of nuclear receptors activate and/or repress gene transcription through direct binding to discrete *cis*-acting elements termed "hormone response elements" (HRE). It has been shown that these HRE's comprise repeats of consensus palindromic hexanucleotide DNA motifs. The specificity of the HRE's is determined by the orientation of, and spacing between, halfsites (i.e. half a palindromic sequence)(Umenesono K., *et al*, 1991 *Cell* **65**, 1255-1266).

Specific DNA binding is mediated by a strongly-conserved DNA binding domain, containing two zinc fingers, which is conserved among all thus discovered nuclear receptors. Three amino acids at the C-terminal base of the first zinc finger (known as the "P-box") are important for the recognition of the half site nucleotide sequence. Members of the nuclear receptor superfamily have been classified into different groups on the basis of the amino acid sequence within the P box.

All members of the nuclear receptor superfamily also contain a hypervariable N-terminal domain and a ligand-binding domain containing some "patches" of conserved sequence. One of these is called the "Ti-domain".

Molecules which are thought to be nuclear receptors, as they are structurally related to characterised receptors, but for which no ligand has been found, are termed "orphan receptors". Many such orphan receptors have been identified (see for example Evans R.M. (1988) *Science* **240**, 889-895 and O'Malley, B. (1990) *Mol.-Endocrinol.* **4** 363-369)

We have now unexpectedly identified, initially in rat a new orphan receptor, which is related to the known estrogen receptor ER α , and which we have designated "ER β " (specifically "rER β " in rat). In this specification "Er β " will be used to refer to the receptors hER β or rER β or related receptors. The nucleotide and amino acid sequences of rER β have now been determined and are shown in Fig. 1. We have also identified a human Er β - "hER β ", the amino acid DNA and sequences of which are shown in Fig. 13A and 13B respectively.

According to one aspect of the invention there is provided a novel estrogen receptor-related nuclear receptor, hereinafter termed "ER β " having the amino acid sequence of Figs. 1, Fig. 13A or 16A or substantially the same amino acid sequence as the amino acid sequence shown in Figs. 1, 13A or 16A or an amino acid sequence functionally similar to those sequence. The isolated receptor may be particularly useful in the search for molecules for use in treatment of diseases or conditions such as cardiovascular diseases, central nervous system diseases or conditions or osteoporosis, prostate cancer or benign prostatic hyperplasia.

The receptor of the invention may also be used in the testing of environmental chemicals for estrogenic activity. There has been increasing concern over the effect of various

chemicals released into the environment on the reproduction of humans and animals.

Threats to the reproductive capabilities of birds, fish, reptiles, and some mammals have become evident and similar effects in humans have been proposed. Substantial evidence is now emerging which shows that exposure to certain chemicals during critical periods of foetal life may distort the development of the reproductive organs and the immune and nervous systems. On the basis of possible parallels between actual wildlife effects, seen for example in birds and seals living in highly polluted areas, and proposed effects in humans, in combination with documented human reproductive effects caused by prenatal exposure to the pharmaceutical estrogen, diethyl stilbestrol (DES), "estrogenic" chemicals have been proposed to threaten the reproductive capability of both animals and humans.

Among the chemicals known or suspected to act as estrogen mimics on the human body, or in other ways disturb the human endocrine system, there are several which have already been identified as environmental hazards. Among the chemicals that have been mentioned as potential causes of disruption of reproductive function in animals and humans are chlorinated organic compounds such as dieldrin, endosulfans, chlordanes, endrins, aldrin, DDT and some PCBs, plastics such as Bisphenol A, phthalates and nonylphenol, and aromatic hydrocarbons. Some of the proposed effects on humans have been suggested to be due to an increasing exposure to environmental estrogens - in fact, exposure to chemical compounds to which higher organisms during the foetal period react in a way that is similar to when they are exposed to high dosages of estrogens. The effects are manifested by for example perturbations of the sex characteristics and impaired reproductive potential. In humans, elevated risks of breast cancer and other hormone-related disease has also been discussed as possible effects. In addition, to the documented "estrogenic" effects, it has recently been demonstrated that environmental

pollutants may also act on hormonal pathways other than the estrogenic pathway - it has been shown that p,p' - DDE the main metabolite of DDT (also in humans) is a fairly anti-androgenic agent (Kelce W.R. *et al* Nature 1995 375:581-585). Epidemiological studies on these issues are, however, presently difficult to interpret. Nevertheless, there is a growing opinion against these potentially hormone disrupting chemicals, and very palpable public and environmental demand for the governmental agencies and industry to act. In view of the similarities between the receptor of the present invention, Er β and the classical estrogen receptor, Er β may be used in the testing of chemicals for estrogenic effect.

An amino acid sequence functionally-similar to the sequence shown in Fig. 1, 13A or 14A may be from a different mammalian species.

An amino acid sequence which is more than about 89%, identical with the sequence shown in Fig. 1, 13A or 14A is substantially the same amino acid sequence for the purposes of the present application. Preferably, the amino acid sequences is more than about 95% identical with the sequence shown in Fig. 1, 13A or 14A.

According to another aspect of the invention there is provided a DNA sequence encoding a nuclear receptor according to the first aspect of the invention. Preferably, the DNA sequence is that given in Fig. 1, 13A or 14A or is a DNA sequence encoding a protein or polypeptide having the functionality of ER β .

ER β is unique in that it is extremely homologous to the rat estrogen receptor, in particular in its DNA binding domain. It appears that ER β has a very limited tissue distribution. In

female rats, it appears to be present only in the ovaries, and in male rats in the prostate and testes. As these tissues are classic targets for estrogen action, it can be deduced that ER β may mediate some of the effects of estrogen.

The different ligand specificity of ER α and ER β may be exploited to design pharmaceutical agents which are selective for either receptor. In particular, the differences in ligand specificity may be used to develop drugs that specifically target cardiovascular disease in postmenopausal women or osteoporosis.

The nuclear receptor of the invention, ER β , a method of producing it, and tests on its functionality will now be described, by way of example only, with reference to the accompanying drawings, Figs. 1 to 15 in which:

Fig. 1 shows the amino acid sequence of ER β and the nucleotide sequence of the gene encoding it;

Fig. 2A is a phylogenetic tree showing the evolution of ER β and other receptors;

Fig. 2B shows the homology between the different domains in ER β and certain other receptors;

Fig. 2C is an alignment of the amino acid sequence in the ligand binding domains of rER β , rER α , mER α and hER α ;

Fig. 2D is an alignment of the amino acid sequence in the DNA binding domains of rER β , rER α , mER α and hER α ;

Fig. 3A is a film autoradiograph of prostate gland showing strong expression of a clone of the receptor of the invention, clone 29;

Fig. 3B is a darkfield image showing prominent signal for clone 29 in epithelium (e) of prostatic-alveoli. The stroma(s) exhibit(s) weaker signal;

Fig. 3C is a bipolarization image of cresyl violet counterstained section showing silver grains over epithelium (e), whereas the stroma(s) contain(s) less grains;

The bar represents 0.7 mm for Fig. 3A, 200 μ m for Fig. 3B and 30 μ m for Fig. 3C;

Fig. 4A shows a film autoradiograph of ovary showing strong expression of clone 29 in follicles at different developmental stages (some are indicated by arrows). The interstitial tissue (arrowheads) shows low signal;

Fig. 4B shows a darkfield image showing high expression of clone 29 in granular cells of primary (1), secondary (2), tertiary (3) and mature (4) follicles. Low signal is present in interstitial tissue (it);

Fig. 4C is a bipolarization image of ovary a showing strong signal in granular cells (gc), whereas the oocyte (oc) and the cainterna (ti) are devoid of clear signal;

The bar represents 0.9 mm for Fig. 4A, 140 μ m for Fig. 4B and 50 μ m for Fig. 4C;

Fig. 5A illustrates the results of saturation ligand binding analysis of cloned ER β ;

Fig. 5B illustrates the specificity of ligand binding by cloned ER β ;

Fig. 5C illustrates E2 binding by ER β ;

Fig. 6 illustrates the activation of transcription by cloned ER β ;

Fig. 7 and 7A illustrates stimulation by various ligands by cloned ER β ;

Fig. 8 illustrates the results of RT-PCR experiments on the expression of rat estrogen receptors;

Fig. 9 illustrates the results of RT-PCR experiments on the expression of human Er β (hER β);

Fig. 10A is a Hill plot comparing binding of 125 I-E2 by hER α and rER β ;

Fig. 10B is a Scatchard plot comparing binding of 125 I-E2 by hER α and rER β ;

Fig. 11A illustrates the relative binding affinity of hER α and rER β for various ligands;

Fig. 11B is a detail of Fig. 12A;

Fig. 12 is an alignment of various estrogen receptors;

Fig. 13A shows the amino acid sequence of human ER β ;

Fig. 13B shows the DNA sequence of human Er β ;

Fig. 14A shows the amino acid sequence of mER β ;

Fig. 14B shows the DNA sequence of mouse Er β ; and

Fig. 15 illustrates ligand binding affinities for various phytoestrogens by ER's of the invention.

A. CLONING OF RAT ER β

1. PCR-amplification and complementary DNA cloning.

A set of degenerate primers (DBD 1,2,3 and WAK/FAK) were designed previously according to the most highly conserved sequences of the DNA-binding domain (P-box) and ligand binding domain (Ti-stretch) of members of the nuclear receptor family (Enmark, E., Kainu, T., Peltö-Huikko, M., & Gustafsson, J.-Å (1994) *Biochem. Biophys. Res. Commun.* **204**, 49-56). Single strand complementary DNA reverse transcribed from rat prostate total RNA was employed with the primers in PCR reactions as described in Enmark, E., Kainu, T., Peltö-Huikko, M., & Gustafsson, J.-Å (1994) *Biochem. Biophys. Res. Commun.* **204**, 49-56. The

amplification products were separated on a 2% low melting agarose gel and DNA products between 400 and 700 bp were isolated from the gel and ligated to TA cloning vector (Invitrogen). As alternatives, we also used the RP-I/RP-2 and DBD66-100/DBD210-238 primer sets in the DNA-binding domain of nuclear receptors exactly as described by Hirose T., Fijimoto, W., Yamaai, T., Kim, K.H., Matsuura, H., & Jetten, A.M (1994) *Mol. Endocrinol.* 8, 1667-1677 and Chang, C., Lopes Da Silva, S., Ideta, R., Lee, Y., Yeh, S., & Burbach, J.P.H (1994) *Proc. Natl. Acad. Sci.* 91, 6040-6044 respectively. Clone number 29 (obtained with the DBD-WAK/FAK set) with a length of 462 bp showed high homology (65%) with the rat estrogen receptor cDNA (65%), which was previously cloned from rat uterus (Koike, S., Sakai, M., & Muramatsu, M. (1987) *Nucleic Acids Res* 15, 2499-2513). The amino acid residues predicted by clone 29 DNA sequences suggested that this DNA fragment encoded part of the DNA-binding domain, hinge region and the beginning of the ligand binding domain of a novel member of the nuclear receptor family. Two PCR primers (Figure 1) were used to generate a probe of 204 bp consisting of the hinge region of the novel receptor, which was used to screen a rat prostate cDNA library (Clontech gt10) under stringent conditions resulting in four strongly positive clones with a size of 0.9 kb, 1.8kb, 2.5kb and 5-6kb respectively. The clone of 2.5kb was sequenced and Figure 1 shows the nucleotide sequence determined in the core facility (CyberGene AB) by cycle sequencing using fluorescent terminators (Applied Biosystems) on both strands, with a series of internal primers and deduced amino acid sequence of clone 29. Two in frame ATG codons are located at nucleotide 424 and nucleotide 448, preceding by an in-frame stop codon at nucleotide 319, which suggests that they

are possible start codons. The open reading frame encodes a protein of 485 amino acid residues (counted from the first methionine) with a calculated molecular weight of 54.2 kDa. Analysis of the proteins synthesized by *in-vitro* translation from the clone 29 cRNA in rabbit reticulocyte lysate revealed a doublet protein band migrating at approximately 57 kDa on SDS-PAGE gels (data not shown), confirming the open reading frame. The doublet protein band is probably caused by the use of both ATG codons for initiation of protein synthesis. The amino acid sequence of clone 29 protein shows the characteristic zinc module DNA-binding domain, hinge region and a putative ligand binding domain, which are the characteristic features of members of the nuclear receptor family (Tsai, M-J., & O'Malley, B.W (1994) *Ann. Rev. Biochem.* 63, 451-486; Härd, T., & Gustafsson, J-Å (1993) *Acc. Chem. Res.* 26, 644-650; Laudet, V., Hänni, C., Coli, J., Catzeflis, F., & Stehelin, D (1992) *EMBL J.* 11, 1003- 1012).

Protein sequence comparison with several representative members of the nuclear receptor family (Figure 2) showed the clone 29 protein is most related to the rat estrogen receptor (ER α), cloned from uterus (Koike, S., Sakai, M., & Muramatsu, M. (1987) *Nucleic. Acids Res.* 15, 2499-2513), with 95% identity in the DNA-binding domain (amino acid residues 103-167) (Griffiths, K., Davies, P., Eaton, C.I., Harper, M.E., Turkes, A., & Peeling, W.B. (1991) in *Endocrine Dependent Tumours*, eds. Voigt, K-D. & Knabbe, C. (Raven Press), pp. 83-125).

A number of functional characteristics have been identified within the DNA-binding domain of nuclear receptors (Härd, T., & Gustafsson, J-Å. (1993) *Acc. Chem. Res.* 26, 644-650 and Zilliacus, J., Carlstedt-Duke, J., Gustafsson, J-Å., & Wright, A.P.H. (1994) *Proc. Natl. Acad. Sci. USA* 91, 4175-4179). The

so-called P-box specifies nucleotide sequence recognition of the core half-site within the response element, while the D- box mediates dimerization between receptor monomers. The clone 29 protein P-box and D-box sequences of EGCKA and-PATNQ, respectively, are identical to the corresponding boxes in ER α (Härd, T., & Gustafsson, J.-Å. (1993) *Acc. Chem. Res* 26, 644-650 and Koike, S., Sakai, M., & Muramatsu, M. (1987) *Nucleic Acids Res.* 15, 2499-2513), thus predicting that clone 29 protein binds to ERE sequences.

The putative ligand binding domain (LBD) of clone 29 protein (amino acid residues 259-457) shows closest homology to the LBD of the rat ER α (Figure 2), while the homology with the human ERR1 and ERR2 proteins (Giguere, V., Yang, N., Segui, P., & Evans R.M. (1988) *Nature* 331, 91-94) is considerably less. With the human, mouse and xenopus estrogen receptors the homology in the LBD is also around 55%, while the homology with the LBD of other steroid receptors is not significant (Figure 2). Cysteine residue 530 in human ER α has been identified as the covalent attachment site of an estrogenic affinity label (Harlow, K.W., Smith D.N., Katzenellenbogen, J.A., Greene, G.L., & Katzenellenbogen, B.S. (1989) *J. Biol. Chem.* 264, 17476- 17485). Interestingly, clone 29 protein (Cys-436) as well as the mouse, rat and xenopus ER α s have a cysteine residue at the corresponding position. Also, two other amino acid residues described to be close to or part of the ligand-binding pocket of the human ER α -LBD (Asp 426 and Gly 521) are conserved in the LBD of clone 29 protein (Asp 333 and Gly 427) and in the LBD of ER α s from various species (20,21). The ligand-dependent transactivation function TAF-2 identified in ER α (Danielian, P.S., White, R., Lees, J.A., & Parker,

M.G. (1992) *EMBO J.* **11**, 1025-1033), which is believed to be involved in contacting other transcription factors and thereby influencing activation of transcription of target genes, is almost completely conserved in clone 29 protein (amino acid residues 441-457). Steroid hormone receptors are phosphoproteins (Kuiper, G., & Brinkmann, A.O. (1994) *Mol. Cell. Endocrinol.* **100**, 103-107), and several phosphorylation sites identified in the N-terminal domain and LBD of ER α (Arnold, S.F., Obourn, J.D., Jaffe, H., & Notides, A.C. (1995) *Mol. Endocrinol.* **9**, 24-33 and Le Goff, P., Montano, M.M., Schodin, D.J., & Katzenellenbogen, B.S (1994) *J. Biol. Chem.* **269**, 4458-4466) are conserved in clone 29 protein (Ser 30 and 42, Tyr 443). Clone 29 protein consists of 485 amino acid residues while ER α s from human, mouse and rat consist of 590-600 amino acid residues. The main difference is a much shorter N-terminal domain in clone 29 protein i.e 103 amino acid residues as compared to 185-190 amino acid residues in the other receptor proteins. Also the non-conserved so-called F-domain at the C-terminal end of ER α s is 15 amino acid residues shorter in clone 29 protein. The cDNA insert of a positive clone of 2.6 kb was subcloned into the EcoR1 site of pBluescript (trademark) (Stratagene). The complete DNA sequence of clone 29 was determined (CyberGene AB) by cycle sequencing using fluorescent terminators (Applied Biosystems) on both strands, with a series of internal primers.

Figs 2C and 2D respectively compare the ligand and DNA binding domain of Er β compared to rat, mouse and human ER α 's.

2. **Saturation ligand binding analysis and ligand competition studies:**

Clone 29 cDNA was subcloned in pBluescript downstream of the T7 promoter to give p29-T7. Clone 29 protein was synthesized *in vitro* using the TnT-coupled reticulocyte lysate system (Promega). Translation reaction mixtures were diluted five times with TEDGMo buffer (40 mM Tris/HCl, pH 7.4, 1mM EDTA, 10% (v/v) glycerol, 10 mM Na₂MoO₄, 10 mM DTT) and 0.1 ml aliquots were incubated for 16 h at 8° C with 0.3- 6.2 nM [2,4,6,7-³H]-17 β -estradiol (NEN-Dupont; specific radioactivity 85 Ci/mmol) in the presence or absence of a 200-fold excess of unlabelled E2.

Fig. 5A illustrates the results of a saturation ligand analysis of clone 29 protein. Reticulocyte lysate containing clone 29 protein was incubated with 6 concentrations of [³H]E2 between 0.3 and 6.0 nM. Parallel tubes contained an additional 200 fold of non-radioactive E2. Bound and free ligand were separated with a dextran-coated charcoal assay. The K_d (0.6 nM) was calculated from the slope of the line in the Scatchard plot shown ($r = 0.93$), and the number of binding sites was extrapolated from the intercept on the abscissa (B_{max} = 1400 fmol/ml undiluted translation mixture).

For ligand competition studies diluted reticulocyte lysate was incubated with 5 nM [2,4,6,7-³H]-17 β -estradiol in the presence of either 0, 5, 50, 500 or 5,000 nM of non- radioactive E2, estrone, estriol, testosterone, progesterone, corticosterone, 5 α -androstane-3 β ,17 β -diol, 5 α -androstane-3 α ,17 β -diol and diethylstilbestrol (DCES) for 16 h at 8°C. Bound and unbound steroids were separated with a dextran-coated

charcoal assay (Ekman, P., Barrack, E.R., Greene, G.L., Jensen, E.V., & Walsh, P.C (1983) *J. Clin. Endocrinol Metab.* 57, 166-176).

Fig. 5B illustrates the specificity of ligand-binding by clone 29 protein.

Reticulocyte lysate containing clone 29 protein was equilibrated for 16 h with 5 nM [³H]E2 and the indicated fold excess of competitors. Data represent [³H]E2 bound in the presence of unlabelled E2, testosterone (T), progesterone (prog), corticosterone (cortico), estrone (E1), diethylstilbestrol (DES), 5 α -androstane-3 α , 17 β -diol (3 α -AD), 5 α -androstane- 3 β , 17 β -diol (3 β -AD) and estriol (E3). [³H]E2 binding in the absence of competitor was set at 100%.

3. *In-situ* hybridisation:

In-situ hybridisation was carried out as previously described (Dagerlind Å., Friberg, K., Bean, A.J., & Hökfelt, T (1992) *Histochemistry* 98, 39-49). Briefly, two oligonucleotide probes directed against nucleotides 994-1041 and 1981-2031 were each labelled at the 3'-end with ³²P-dATP using terminal deoxynucleotidyltransferase (Amersham, UK). Adult male and female Sprague-Dawley rats (age 2 to 3 months n=10) were used for this study. The rats were decapitated and the tissues were rapidly excised and frozen on dry ice. The tissues were sectioned in a Microm HM500 cryostat at 14 μ m and thawed onto Probe-On glass slides (Fisher Scientific, PA, USA). The slides were stored at -20°C until used. The slides were incubated in humidified boxes at 42°C for 18 h with 1x10⁶ cpm of the probe in a hybridization solution containing 50% formamide, 4 x SSC (1 x SSC = 0.15 M NaCl, 0.015 M sodium citrate), 1 x

Denhardt (0.02 % BSA, 0.02 % Ficoll, 0.02 % PVP), 1 % sarkosyl. 0.02 M sodium phosphate (pH 7.), 10% dextranulphate, 500 µg/ml salmon sperm DNA and 200 mM DTT. Slides were subsequently rinsed in 1 x SSC at 55°C for 60 min with four changes of SSC and finally in 1 x SSC starting at 55°C and slowly cooled to room temperature, transferred through distilled water and briefly dehydrated in 50% and 95% ethanol for 30 sec each, air-dried, and covered with Amersham β-man autoradiography film for 15 to 30 days. Alternatively the slides were dipped in Kodak NTB2 nuclear track emulsion (diluted 1:1 with distilled water) and exposed for 30 to 60 days at 4°C. Finally, the sections were stained with cresyl violet.

Clear expression of clone 29 was observed in the reproductive tract of both male and female rats, while in all other rat tissues the expression was very low or below the level of detection with *in-situ* hybridisation (not shown). In male reproductive organs high expression was seen in the prostate gland (Figure 3), while very low expression was observed in testis, epididymis and vesicula seminalis (not shown). In dipped sections, expression was clearly visible in prostate epithelial cells (secreting alveoli) while the expression in smooth muscle cells and fibroblasts in the stroma was low (Figure 3). In female reproductive organs expression was seen in the ovary (Figure 4), while uterus and vagina were negative (not shown). In dipped sections high expression was seen in the granulosa cell layer of primary, secondary and mature follicles (Figure 4), whereas primordial follicles, oocytes and corpora lutea appeared completely negative. Low expression was seen in the interstitial cells of the ovary. Both anti-sense oligonucleotide probes used

produced similar results. Addition of a 100 fold excess of the respective unlabelled oligonucleotide probes during the hybridisation reactions abolished all signals.

4. Transactivation analysis in CHO-cells:

The expression vector pCMV29 was constructed by inserting the 2.6 kb clone 29 fragment in the EcoRI site of the expression vector pCMV5 (Andersson, S., Davis, D.L., Dahlbäck, H., Jörnvall, H., & Russell, D.W. (1989) *J. Biol. Chem.* 264, 8222-8229). The pERE-ALP reporter construct contains a secreted form of the placental alkaline phosphatase gene (Berger, J., Hauber, J., Hauber, R., Geiger, R., & Cullen, B.R. (1988) *Gene* 66, 1-10) and the MMTV-LTR in which the glucocorticoid response elements were replaced by the vitellogenin promoter estrogen response element (ERE).

CHO-K1 cells were seeded in 12-well plates at approximately 1.7×10^5 cells per well in phenol-red free Ham F12 medium with 5% FCS (dextran-coated charcoal treated) and 2 mM Lglutamine. After 24 h the cells were transfected with 250 ng pERE-ALP vector and 50 ng pCMV29 using lipofectamine (Gibco) according to the manufacturer's instructions. After five hours of incubation the cells were washed and refed with 0.5 ml phenol-red free Coon's F-12 medium containing 5% serum substitute (SRC 3000, Tissue Culture Services Ltd., Botolph Claydon, Buckingham, UK) 2 mM Lglutamine and 50 µg/ml gentamicin plus hormones as indicated. After 48 h the medium was assayed for alkaline phosphatase (ALP) activity by a chemiluminescence assay. A 10 µl aliquot of the cell culture medium was mixed with 200 µl assay buffer (10 mM diethanolamine pH 10.0 1 mM $MgCl_2$ and 0.5 mM CSPD (Tropix Inc. Boston. USA)) and incubated for 20 min at 37°C

before measurement in a microplate luminometer (Luminoskan; Labsystems, Finland) with integral measurement for 1 second. The ALP activity of ERE-reporter alone was set at 1.

5. **Ligand binding characteristics and transactivation function of clone 29**

protein:

On the basis of the described high homology between clone 29 protein and rat ER α in the DBD and LBD it was hypothesized that clone 29 protein might encode a novel ER. Furthermore, biological effects of estrogens on rat prostate and ovary, which show high expression of clone 29 RNA, are well known (Griffiths, K., Davies, P., Eaton, C. I., Harper, M.E., Turkes, A., & Peeling W. B. (1991) in *Endocrine Dependent Tumours*, eds Voigt, K-D. & Knabbe, C. (Raven Press), pp 83-125; Richards, J.S (1994) *Endocrine Rev.* **15**, 725-745; and Habenicht, U-F., Tunn, U.W., Senge, Th., Schroder, R.H., Schweikert, H.U., Bartsch, G., & El Etreby, M.F. (1993) *J. Steroid Biochem. Molec. Biol.* **44**, 557-563). In order to analyze the steroid binding properties of clone 29 protein synthesized *in vitro*, the reticulocyte lysate was incubated at 8°C for 16 h with increasing concentrations (0.3-6.0 nM) of [³H]E2 in the presence or absence of a 200 fold molar excess of unlabelled E2. Linear transformation of saturation data revealed a single population of binding sites for E2 with a K_d (dissociation constant) of 0.6 nM (Figure 5A and C). Steroid binding specificity was measured by incubating reticulocyte lysate with 5 nM [³H]E2 in the presence of 0.5, 50, 500 and 5,000 nM unlabelled competitors. Competition curves generated are indicative of an estrogen receptor in that only estrogens competed efficiently with [³H]E2 for binding

(Figure 5B). Fifty percent inhibition of specific binding occurred by 0.6 fold excess of unlabelled E2; diethylstilbestrol, estriol, estrone and 5 α -androstane-3 β ,17 β -diol were 5, 15, 50 and 150 times, respectively, less effective as competitors. Neither testosterone, progesterone, corticosterone nor 5 α -androstane-3 α ,17 β -diol were efficient competitors, even at the highest concentrations used (1000 fold excess). The dissociation constant and the steroid binding specificities measured are in good agreement with data previously reported for ERs in rat and human prostate, rat granulosa cells, rat antral follicles and whole rat ovarian tissue (Ekman, P., Barrack, E.R., Greene, G.L., Jensen, E.V., & Walsh, P.C (1983) *J. Clin. Endocrinol. Metab.* **57**, 166-176; van Beurden-Lamers, W.M.O., Brinkmann, A.O., Mulder, E., & van der Molen, H. (1974) *Biochem. J* **140**, 495-502; Kudolo, G.B., Elder, M.G., & Myatt, L. (1984) *J. Endocrinol.* **102**, 83-91; and Kawashima, M., & Greenwald, G.S. (1993) *Biology of Reprod.* **48** 172-179).

When clone 29 protein was labelled with a saturating dose of [³H]E2 and analyzed on sucrose density gradients, a single peak of specifically bound radioactivity was observed. The sedimentation coefficient of this complex was about 7S, and it shifted to 4S in the presence of 0.4 M NaCl (not shown). To investigate the transcriptional regulatory properties of clone 29 protein, we performed co-transfection experiments in which CHO cells were transfected with a clone 29 protein expression vector and/or an estrogen-responsive reporter gene construct. Cells were incubated in the absence of E2 (clone 29) or in the presence of 100 nM E2 (Clone 29 + E2) or in the presence of 100 nM E2 and 12 μ M Tamoxifen (Clone 29 + E2/Tam). In the absence of exogenously added E2 clone 29 protein showed

considerable transcriptional activity which could be further increased by the addition of 100 nM E2 (Figure 6). Simultaneous addition of a 10 fold excess of the antiestrogen Tamoxifen partially suppressed the E2 stimulated activity (Figure 6).

The constitutive transcriptional activity of clone 29 protein could be suppressed by the anti-estrogen ICI-1624384 (not shown). It has been shown previously that the wild-type mouse and human ERs are constitutive activators of transcription, and that the transcriptional activity can be stimulated further by the addition of E2 (Txukerman, M., Xiao-Kun Zhang., Hermann, T., Wills, K. N., Graupner, G., & Phal, M. (1990) *New Biologist* 2, 613-620 and Lees, J.A., Fawell, S.E., & Parker, M.G. (1989) *Nucl. Acids Res.* 17, 5477-5488). To obtain more insight into what concentrations of E2 effect clone 29 protein transcriptional activity, transient transfection experiments were carried out in the presence of increasing concentrations of E2. CHO-cells were transiently transfected with the ERE-reporter plasmid and the clone 29 protein expression plasmid. Cells were incubated with increasing concentrations of E2 (0.1 - 1000 nM), estrone (E1, 1000 nM), 5 α -androstane-3 β ,17 β -diol (3 β -AD, 1000 nM) or no ligand added. Alkaline phosphatase activity (ALP) was measured as described and the activity in the absence of ligand (control) was set at 1. The figure shows relative ALP-activities (\pm SD) from three independent experiments. Clone 29 protein began to respond at 0.1 nM E2 and maximal stimulation was observed between 1 nM and 10 nM E2 (Figure 7). The maximal stimulation factor was 2.6 ± 0.5 fold (mean \pm SD, n = 9) as compared to incubation in the absence of E2. Apart from E2 also estrone and 5 α -androstane- 3 β ,17 β -diol could stimulate transcriptional activity, albeit at higher concentrations (Figure 7). Dexamethasone, testosterone, progesterone,

5 α -androstane-3 α ,17 β -diol, thyroid hormone and all-*trans*-retinoic acid could not stimulate transcriptional activity of clone 29 protein, even at the highest concentration (1000 nM) tested (not shown). The results of the co-transfection experiments are in agreement with the ligand binding and specificity data of clone 29 protein presented in Figure 5. In control experiments, wild-type human ER α also showed transcriptional activity in the absence of E2, which could be increased by the addition of E2 (not shown).

6. Detection of rat ER expression by RT-PCR

The tissue specificity of expression of rat ER β and ER α was determined using reverse transcriptase polymerase chain reaction (RT-PCR). The results of the experiment are shown in Fig. 8.

B. Isolation of human Er β

1. A human version of Er β (hER β) has also been cloned from human ovary. The tissue specificity of hER β expression in a variety of cells was also determined using the RT-PCR technique. The results are shown in Fig. 9. It will be noticed that there is a very high level of mRNA of hER β in human umbilical vein endothelial cells (HUVEC) but no detection of hER α in the same cells. In addition, it will be seen that in human osteosarcoma cell line (HOS-D4), hER β is expressed in greater quantities compared to hER α .

- I. A human version of ER β (hER β) has also been cloned. The tissue specificity of hER β expression in a variety of cells was also determined using the

RT-PCR technique. The results are shown in Fig. 9. It will be noticed that there is a very high level of mRNA of hER β in human umbilical vein endothelial cells (HUVEC) but no detection of hER α in the same cells. In addition, it will be seen that in human osteosarcoma cell line (HOS-D4), hER β is expressed in greater quantities compared to hER α .

The partial DNA sequence of hER β is shown in Fig. 10 and a derived amino acid sequence is shown in Fig. 11.

Cloning of human Er β from testis

A commercially available cDNA from human testis (Clontech, article no. HL1161x) was screened, using a fragment containing the ligand-binding domain of the rat Er β cDNA as probe. Approximately 10^6 recombinants were screened, resulting in one positive clone. Upon sequencing of this clone, it was seen that the insert was 1156 bp (Figure 13A and 13B). This corresponds to most of the translated region of a receptor with an overall homology of 90.0% to rat Er β , therefore deduced to represent the human form of Er β .

The cloned hER β , however, lacks approximately 47 amino acids at the N-terminal end and 61 amino acids at the C-terminal end (as compared to the rat sequence). Further screening of the same library was unsuccessful. PCR technology was therefore used to obtain the remaining parts. For

oligonucleotides were synthesised; two degenerate oligonucleotides containing all possible codons for the amino acids adjacent to the initiation methionine and the stop codon, respectively, of the rat Er β , and two specific oligonucleotides containing the sequence of the clone isolated from the human testis library and situated approximately 100 bp from respective end of this clone. PCR with the N-terminal and C-terminal pair of oligos yielded specific bands, that were subcloned and sequenced. The parts of these new clones that overlap the original cDNA clone are identical to this. It was thus possible to construct peptide and DNA sequences corresponding to the whole open reading frame (Fig. 13A and 13B).

When comparing the human Er β to rat Er β , this receptor is 79.6% identical in the N-terminal domain, 98.5% in the DNA-binding domain, 85.6% in the hinge and 91.6% in the ligand-binding and F-domains. These numbers match very well those found when comparing the rat and human forms of Er α .

Studies of the expression of human Er β using Northern blot show expression in testis and in ovaries. The expression in prostate, however, appears lower than found in the rat.

The human $Er\beta$ gene has been mapped to chromosome 14 using PCR and to region 14q22-23 using the FISH technique, whereas the human $Er\beta$ gene has been mapped to chromosome 6q25.

2. Comparison of ligand binding affinity of $hER\alpha$ and $rER\beta$

The ligand affinity of the two estrogen receptors, human $Er\alpha$ (ovary) ($hER\alpha$) and rat $Er\beta$ ($rER\beta$) was tested in binding saturation experiments and in binding competition experiments.

cDNA of the receptor subtypes $hER\alpha$ and $rER\beta$ were *in vitro* translated in rabbit reticulocyte lysate in presence of non-radioactive amino acids according to the instructions supplied by the manufacturer (Promega).

The radioactive ligand used in all experiments was 16α -[^{125}I]- 17β -estradiol ([^{125}I]-E2) (NEX- 144, New England Nuclear). The method for the binding experiments was previously described in: Salomonsson M, Carlsson B, Haggblad J. J. *Steroid Biochem. Molec. Biol.* Vol. 50, No. 5/6 pp. 313-18, 1994. In brief, estrogen receptors are incubated with [^{125}I]-E2 to equilibrium (16-18 h at +4°C). The incubation was stopped by separation of protein-bound [^{125}I]-E2 from free [^{125}I]-E2 on Sephadex G25 columns. The radioactivity of the eluate is measured in a gamma-counter.

In the competition experiments, non-radioactive ligands were diluted in DMSO, mixed with [^{125}I]-E2 (approximately 100-200 pM), aliquoted in

parallel, and finally hER α or rER β was added. The final concentration of DMSO in the binding buffer was 2%.

The buffer used in the experiments was of the following composition:

Hepes (pH=7.5) 20 mM, KCl 150 mM, EDTA 1 mM, glycerol (8.7%), monothioglycerol 6 mM, Na₃MO₄ 10 mM.

3. Equilibrium binding saturation experiments (K_d -determinations)

A range of concentrations of [¹²⁵I]-E2 were mixed with the ER:s and incubated as described above, free [¹²⁵I]-E2 was determined by subtracting bound [¹²⁵I]-E2 from added [¹²⁵I]-E2. Binding data was analysed by Hill-plots and by Scatchard plots (Figure 11). The equilibrium binding results are shown in Table 1. The apparent K_d -values for [¹²⁵I]-E2 differed between the two ER:s with approximately a factor of four: $K_d(\text{hER}\alpha):K_d(\text{rER}\beta) = 1:4$.

Table 1. Equilibrium dissociation constants for [¹²⁵I]-E2 to the two subtypes.

Receptor subtype	K_d (Hill-plot)	K_d (Scatchard-plot)
hER α	0.06 nM	0.09 nM
rER β	0.24 nM	0.42 nM

4. Competition experiments (IC_{50} determinations)

The experiments were performed as described above. IC_{50} values were obtained by applying a four parameter logistic analysis; $b = ((b_{max} - b_{min}) / (1 + (L/IC_{50})^S)) + b_{min}$, where L is the added concentration of binding inhibitor, IC_{50} is the concentration of inhibitor at half maximal binding and S is a slope factor. The free concentration of $[^{125}I]$ -E2 was determined by sampling an aliquot from the wells at the end of the incubation and then subtract bound radioactivity from sampled total radioactivity.

Since the equilibrium binding experiments (above) showed that the K_d -values for $[^{125}I]$ -E2 differed between the two ER:s, K_i -values (from the Cheng-Prusoff equation: $K_i = IC_{50} / (1 + L/K_d)$ where L is free ($[^{125}I]$ -E2)) were calculated for the compounds investigated. Two approaches for calculating RBA (Relative Binding Affinity) were used. The RBA values were derived using either the IC_{50} values or the K_i values. In both approaches, the value for the compound 16 α -bromo-estradiol was selected as the reference value (100%). Both approaches gave similar results. The results are summarized in Figure 12. In these Figures "4-OH-Tam" = 4-hydroxy-tamoxifen; "DES" = diethylstilbestrol; "Hexestr" = hexestrol; "ICI-164384" = ICI plc compound no. 164382; "17 β -E2" = 17 β -estradiol; "16 α -B-E2" = 16 α -bromo-estradiol; "Ralox" = Raloxifen; and "17 α -E2" = 17 α diol.

The results show that ER α and ER β have significant different ligand binding affinities - the apparent K_d -values for $[^{125}I]$ -E2 differed between the two ER's by a factor of about 4 (K_d (hER α): K_d (rER β) \approx 1:4). Some compounds investigated

showed significant differences in the competition for binding of [125 I]-E2 to the ER's. Certain compounds were found to be more potent inhibitors of [125 I]-E2 binding to hER α as compared to rER β whereas others were found to be more potent inhibitors of [125 I]-E2 binding to rER β than to hER α .

CLAIMS

1. A receptor, ER β , having the amino acid sequence of Figs. 1, 13A or 14A or substantially the same amino acid sequence as the amino acid sequence shown in Figs 1, 13A or 14A or an amino acid sequence functionally similar to those sequences.
2. A receptor according to claim 1 having an amino acid sequence which is more than 95%, identical with the sequence shown in Figs. 1, 13A or 14A.
3. A receptor according to claim 1 or 2 which is derived from rat or human cells.
4. A receptor according to claim 1, 2 or 3 which is an estrogen receptor.
5. A DNA sequence encoding a receptor according to claim 1, 2, 3, or 4.
6. A DNA sequence according to claim 5 in which the DNA sequence is that given in Figs. 1, 13B or 14B or is a DNA sequence encoding a protein or polypeptide having the functionally of ER β .
7. The use of a receptor according to claim 1, 2, 3 or 4 or a DNA sequence according to claim 5 or 6 in an assay to determine molecules which bind Er β .
8. The use of a receptor according to claim 1, 2, 3 or 4 or a DNA sequence according to claim 5 or 6 in an assay to determine molecules for use in the treatment of Er α or Er β specific diseases or conditions.

9. The use of a receptor according to claim 1, 2, 3 or 4 or a DNA sequence according to claim 5 or 6 in an assay to determine molecules for use in treatment of prostate or ovarian cancer, benign prostatic hyperplasia, diseases of the central nervous system, osteoporosis, or cardiovascular disease.
10. A drug design method comprising comparing binding of a test compound to ER α and to ER β .
11. hER β and functional equivalents thereof.
12. The use of a receptor according to claim 1, 2, 3 or 4 in the testing of the possible estrogenic or other hormonal effect of a substance.

1/17

SUBSTITUTE SHEET (RULE 26)

2/17

FIG. 2A





FIG. 2B

ALIGNMENT OF ERβ TO OTHER
ESTROGEN RECEPTORS



3/17

Ligandbinding domain

ELVHMIGWAKKIPGFFVELSLLDQVRLLLESCWMEVLMVGLMWRSDHPGKL	ER8 rat
.....N.....RV.....GD.N.H.....H.....CA.L.I.....I.....V.....ME.....	ER rat
.....N.....RV.....GD.N.H.....H.....CA.L.I.....I.....V.....ME.....	ER mouse
.....N.....RV.....D.T.H.....H.....CA.L.I.....I.....V.....ME.....	ER human
IFAPDLVLDREGEKCVGEILEIFDMLLATTSRFRLEKQHKKEYLCVKAMI	ER8 rat
L.....N.L.....NQ.....MV.....S.....MMN.....GE.FV.L.SI.	ER rat
L.....N.L.....NQ.....MV.....S.....MMN.....GE.FV.L.SI.	ER mouse
L.....N.L.....NQ.....MV.....S.....MMN.....GE.FV.L.SI.	ER human
LLNSSMYP-LASANQEAESSRKLTHTLLNAVTDALVWVVIKSGISSQQQSV	ER8 rat
.....GV.TF.S.TLKSL.EKDHIHRV.DKIN.T.IHLM.....A.LTL.....HR	ER rat
.....GV.TF.S.TLKSL.EKDHIHRV.DKI.T.IHLM.....A.LTL.....HR	ER mouse
.....GV.TF.S.TLKSL.EKDHIHRV.DKI.T.IHLM.....A.LTL.....HQ	ER human
RLANLLMLLSHVRIISNKGMEHLLLSMKCKKNVVPVYDLLLLLEMLNAHTLRG-	ER8 rat
.....Q.....LI.....I.....M.....YN.....L.....D.....R.HAP	ER rat
.....Q.....LI.....I.....M.....YN.....L.....D.....R.HAP	ER mouse
.....Q.....LI.....I.....M.....Y.....L.....D.....R.HAP	ER human
TAF-2	
-YKSSISGSECSSTE-DSKNKESQNLS-----Q	ER8 rat
ASRMGVPPPE.P.QSGLTTTSST.AHS..TYIIPPEAEGFPNTI	ER rat
ASRMGVPPPE.P.QQLATTSST.AHS..TYIIPPEAEGFPNTI	ER mouse
TSRGGGA.VE.TDQSHLATAGST..HS..KYIITGEAEGFPATV	ER human

FIG. 2C

5 / 17



FIG. 3A



FIG. 3B




FIG. 3C




FIG. 4A




FIG. 4B





FIG. 4C


6/17

SCATCHARD PLOT OF ER-BETA





ER-BETA LIGAND SPECIFICITY

FIG. 5B




7/17




8/17

FIG. 7



E2 STIMULATED TRANSACTIVATION

FIG. 7A



9 / 17

DETECTION OF RAT ER EXPRESSION BY RT-PCR.




FIG. 8

10 / 17

DETECTION OF HER EXPRESSION BY RT-PCR.




FIG. 9

FIG. 10A

11/17



HILL PLOT COMPARING hER α AND rER β .

FIG. 10B

SCATCHARD PLOT COMPARING hER α AND rER β .

SUBSTITUTE SHEET (RULE 26)

FIG.11A

12 / 17





FIG.11B



13 / 17

FIG. 12

Alignment Report of E-15, plus 1 file, small, using Clustal method with PAM; 50 residue weight table, conducted 12 august 1996 11:47

[illegible]

14 / 17

1 MTFYSPAVMN YSIPSNVTNL EGGPGRQTT S PNVLWPTPGH LSPLVVRQL
 51 SHLYAEPQKS PWCEARSLEH TLPVNRETLK RKVSGNRCAS PVTGPGSKRD
 101 AHFCAVCS DY ASGYHYGVWS CEGCKAFFKR SIQGHNDYIC PATNQCTIDK
 151 NRRKSCQACR LRKCYEVMV KCGSRRERCG YRLVRRQRSA DEQLHCAGKA
 201 KRSGGHAPRV RELLLDALSP EQLVLTLL EA EPPHVLISRP SAPFTEASMM
 251 MSLTKLADKE LVHMISWAKK IPGFVELSLF DQVRLLESCW MEVLMMGLMW
 301 RSIDHPGKLI FAPDLVLD RD EGKCV EGILE IFDMLLATTS RFRELKLQHK
 351 EYLCVKAMIL LNSSMYPLVT ATQDADSSRK LAHLLNAVTD ALVWVIKSG
 401 ISSQQQSMRL ANLLMLLSHV RHASNKGMEH LLNMKCKNVV PVYDLLLEML
 451 NAHVLRGCKS SITGSECS PA EDSKSKEGSQ NLQSQ*

FIG. 13A

MAFYSPAVMNYSVPSSSTGNLEGGPVRQTASPNVLWPTSGH 40
 LSPLATHCQSSLLYAEPQKSPWCEARSLEHTLPVNRETLK 80
 RKLGGSGCASPVTSPSTKRDAHFCAVCS DYASGYHYGVWS 120
 CEGCKAFFKR SIQGHNDYICPATNQCTIDKNRRKNCQACR 160
 LRKCYEVMVKCGSRRERCGYRIVRRQRSASEQVHCLNKA 200
 KRTSGHTPRVKELLLNSLSPEQLVLTLLAEPPNVLVSRP 240
 SMPFTEASMMMSLTKLADKELVHMIGWAKKIPGFVELSLL 280
 DQVRLLESCWMEVLMVGLMWRSIDHPGKLIFAPDLVLD RD 320
 EGKCV EGILEIFDMLLATTA RFRELKLQHK EYLCVKAMIL 360
 LNSSMYHLATASQEAESSRKLTHLLNAVTDALVWVISKSR 400
 ISSQQQSVRLANLLMLLSHV RHISNKGMEHLLSMKCKNVV 440
 PVYDLLLEMLNAHTLRGYKSSISGSGCCSTEDSKSKEGSQ 480
 NLQSQ. 486

FIG. 14A

15 / 17

1	CTATGACATT	CTACAGTCCT	GCTGTGATGA	ATTACAGCAT	TCCCAGCAAT
51	GTCACATACT	TGGAAGGTGG	GCCTGGTCGG	CAGACCACAA	GCCCAAATGT
101	GTTGTGGCCA	ACACCTGGGC	ACCTTTCTCC	TTTAGTGGTC	CATCGCCAGT
151	TATCACATCT	GTATGCGGAA	CCTCAAAGA	GTCCCTGGTG	TGAAGCAAGA
201	TCGCTAGAAC	ACACCTTACC	TGTAAACAGA	GAGACACTGA	AAAGGAAGGT
251	TAGTGGGAAC	CGTTGCGCCA	GCCCTGTTAC	TGGTCCAGGT	TCAAAGAGGG
301	ATGCTCACTT	CTGCGCTGTC	TGCAGCGATT	ACGCATCGGG	ATATCACTAT
351	GGAGTCTGGT	CGTGTGAAGG	ATGTAAGGCC	TTTTTTAAAA	GAAGCATTCA
401	AGGACATAAT	GATTATATTT	GTCCAGCTAC	AAATCAGTGT	ACAATCGATA
451	AAAACCGGCG	CAAGAGCTGC	CAGGCCTGCC	GACTTCGGAA	GTGTTACGAA
501	GTGGGAATGG	TGAAGTGTGG	CTCCCGGAGA	GAGAGATGTG	GGTACCGCCT
551	TGTGCGGAGA	CAGAGAAGTG	CCGACGAGCA	GCTGCACTGT	GCCGGCAAGG
601	CCAAGAGAAG	TGGCGGCCAC	GCGCCCCGAG	TGCGGGAGCT	GCTGCTGGAC
651	GCCCTGAGCC	CCGAGCAGCT	AGTGCTCACC	CTCCTGGAGG	CTGAGCCGCC
701	CCATGTGCTG	ATCAGCCGCC	CCAGTGCGCC	CTTCACCGAG	GCCTCCATGA
751	TGATGTCCCT	GACCAAGTTG	GCCGACAAGG	AGTTGGTACA	CATGATCAGC
801	TGGGCCAAGA	AGATTCCCGG	CTTTGTGGAG	CTCAGCCTGT	TCGACCAAGT
851	GCGGCTCTTG	GAGAGCTGTT	GGATGGAGGT	GTTAATGATG	GGGCTGATGT
901	GGCGCTCAAT	TGACCACCCC	GGCAAGCTCA	TCTTTGCTCC	AGATCTTGTT
951	CTGGACAGGG	ATGAGGGGAA	ATGCGTAGAA	GGAATTCTGG	AAATCTTTGA
1001	CATGCTCCTG	GCAACTACTT	CAAGGTTTCG	AGAGTTAAAA	CTCCAACACA
1051	AAGAATATCT	CTGTGTCAAG	GCCATGATCC	TGCTCAATTC	CAGTATGTAC
1101	CCTCTGGTCA	CAGCGACCCA	GGATGCTGAC	AGCAGCCGGA	AGCTGGCTCA
1151	CTTGCTGAAC	GCCGTGACCG	ATGCTTTGGT	TTGGGTGATT	GCCAAGAGCG
1201	GCATCTCCTC	CCAGCAGCAA	TCCATGCGCC	TGGCTAACCT	CCTGATGCTC
1251	CTGTCCCACG	TCAGGCATGC	GAGTAACAAG	GGCATGGAAC	ATCTGCTCAA
1301	CATGAAGTGC	AAAAATGTGG	TCCCAGTGTA	TGACCTGCTG	CTGGAGATGC
1351	TGAATGCCCC	CGTGCTTCGC	GGGTGCAAGT	CCTCCATCAC	GGGGTCCGAG
1401	TGCAGCCCGG	CAGAGGACAG	TAAAAGCAAA	GAGGGCTCCC	AGAACCTACA
1451	GTCTCAGTGA				

FIG. 13B

16 / 17

ATGGCATTTCTAC AGTCCTGCTGTG ATGAACTACAGT GTTCCAGCAGC ACCGGTAACCTG GAAGGTGGGCT 72
GTTCCGCCAGACT GCAAGCCCAAT GTGCTATGGCA ACCTCTGgACAC CTCTCTCCTTTA GCCACCCACTGC 144
CAATCATCGCTT CTCTATGCAGAA CCTCAAAAGAGT CCTTGGTGTGAA GCAAGATCACTA GAACACACCTTG 216
CCTGTAACAGA GAGACCTGAG AGGAAGCTTGGC GGAGcGTTGT GCGAGCCCTGTT ACTAGTCCAAGC 288
ACCAAGAGGGAT GCTCACCTTCTGT GCCGTCTGCAGT GATTATGCATCT GGGTATCATTAC GGTGTCTGGTCC 360
TGTGAAGGATGT AAGGCCCTTTT AAAGAAGAGCATT CAAGGACATAAT GACTATATCTGT CCAGCCACGAAT 432
CAGTGTACGATA GACAAGAACCg CGTAAAAACTGC CAGGCCCTGCCA CTTCGCAAGTGT TACGAAGTAGGA 504
ATGGTCAAGTGT GGATCCAGGAGA GAAAGGTGTGG TACCGAATAGTA CGAAGACAGAGA AGTGCCAGCGAG 576
CAGGTGCATTGC CTGAACAAAGCC AAGAGAACCAGT GGGCACACACC CGGTGAAGGAG CTACTGCTGAAC 648
TCTCTGAGTCCC GAGCAGcTGGTG CTCACCCCTGCTG GAAGCTGAGCCA CCCAATGTGCTA GTGAGTCGTCCC 720
AGCATGCCCTTC ACGAGGCCCTCC ATGATGATGTCC CTTACGAAGCTG GCTGACAAGGAA CTGGTGACATG 792
ATTGGCTGGCC AAGAAATCCCT GGCTTTGTGGAG CTCAGCCTGTTG GACCAAGTCCGC CTCTTGGAAAGC 864
TGCTGGATGGAG GTGCTGATGGTG GGGCTGATGTGG CGCTCCATCGAC CACCCCGGCAAG CTCATCTTTGCT 936
CCAGACCTCGT CTGGACAGGGAT GAGGGGAAGTGC GTgGAAGGGATt cTGGAAATCTTT GaCATGCTCCTG 1008
GCgACGACGGCA CGTTCCGTGAG TTAAGACTGCAG CACAAAGAATAT CTGTGTGTGAAG GCCATGATTCTC 1080
CTCAACTCCAGT ATGTACCCTTG GCTACCCGCAAGC CAGGAAGCAGAG AGTAGCCGGAAG CTGACACACCTA 1152
TTGAACGCAGTG ACAGATGCCCTG GTCTGGGTGATT TCGAAGAGTAGA ATCTCTTCCcAG CAGCAGTcaGTC 1224
CGTCTGGCCAAC CTCCTGATGCTt CTTtCTCATGTC AGGCACATCAGT AAcAgGGCATG GAACATCTGCTC 1296
AGCATGAAGTGC AAAAATGTGGTC CCGGTGTACGAC CTGCTGCTGGAG ATGCTGAATGCT CACACGCTTGA 1368
GGGTACAAGTCC TCAATCTCGGg TCTGgGTGCTGC TCGACAGAGGAC AGTAAGAGCAAA GAGGGCTCCCAG 1440
AACCTCCAGTCT CAGTGA 1458

FIG. 14B

17/17

CPD	logIC50 hER α	log IC50 hER β	IC50 (nM) hER α	IC50 (nM) hER β	Ki (nM) hER α	Ki (nM) hER β	RBA(%,) Ki hER α	RBA(%,) Ki hER β	RBA(%,) IC50 hER α	RBA(%,) IC50 hER β
Di-Hydroapoandrostenedione	-6.31	-6.73	485.29	187.11	245.31	163.33	0.027	0.115	0.027	0.115
Testosterone	-5.00	-5.66	10000.00	2187.76	5750.97	1937.70	0.001	0.010	0.001	0.010
Di-Hydrotestosterone	-6.36	-7.08	436.52	83.95	220.66	73.28	0.030	0.256	0.030	0.256
4-OH-Estradiol	-8.78	-8.67	1.66	2.14	0.95	1.89	6.934	9.892	7.889	10.037
19-Nor testosterone	-5.82	-7.22	1513.56	60.12	765.10	52.48	0.009	0.357	0.009	0.357
5 β -Androstane-3-one	>-4	>-4	>100000	>100000	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%
Cypoteroneacetate	>-4	>-4	>100000	>100000	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%
6-4 androstene 3,17, dione	>-4	>-4	>100000	>100000	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%
Progesterone	>-4	>-4	>100000	>100000	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%
Corticosterone	>-4	>-4	>100000	>100000	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%
Genistein	-8.35	-9.41	4.47	0.39	2.57	0.34	2.576	54.361	2.931	55.157
β -sitosterol	>-4	>-4	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%	<0.0002%	<0.0002%
norethynodrel	-7.53	-7.20	29.51	63.10	14.22	53.09	0.466	0.353	0.444	0.340
norethindrone	-6.50	-5.89	316.23	1288.25	152.32	1083.89	0.043	0.017	0.041	0.017
β -zeaxanol	-8.89	-9.00	1.29	0.99	0.78	0.87	8.457	21.465	10.162	21.657
D-4 androstene 3 β ,17 β -diol	-7.33	-7.64	46.77	22.91	23.39	18.71	0.283	1.001	0.280	0.937
dieneol	-10.03	-10.46	0.09	0.03	0.05	0.03	140.523	661.418	138.995	618.871
Methoxychlor	-5.45	-6.96	3548.13	109.65	1774.07	89.56	0.004	0.209	0.004	0.196
Bisphenol A	-6.41	-7.37	389.05	42.66	194.52	34.84	0.034	0.538	0.034	0.503
Ecdysterone*	>-4	>-4	>100000	>100000	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%
Eudesmine	>-4	>-4	>100000	>100000	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%
Lapidine	>-4	>-4	>100000	>100000	>100000	>100000	<0.0002%	<0.0002%	<0.0002%	<0.0002%
Tschimgine	-7.18	-6.63	66.07	234.42	40.13	206.47	0.165	0.091	0.198	0.092
Tschimganidine	-7.87	-6.45	13.49	354.81	8.19	312.50	0.808	0.060	0.971	0.060
Ferutinine	-9.10	-9.56	0.79	0.27	0.40	0.24	16.623	78.091	16.623	78.091
Coumestrol	-9.65	-10.12	0.22	0.08	0.14	0.07	48.665	282.307	58.479	284.839
Nafoxidine	-9.32	-9.05	0.48	0.90	0.24	0.78	27.530	23.966	27.530	23.966
16a-Br-E2	-9.88	-9.67	0.13	0.21	0.07	0.19	100.000	100.000	100.000	100.000
17a-E2	-9.44	-8.88	0.36	1.32	0.22	1.16	30.006	16.133	36.058	16.278
17 β -E2	-9.68	-9.87	0.21	0.13	0.13	0.12	52.145	157.660	62.661	159.074
*1 β -Ecdysone, 20_Hydroxyecdysone										
RBA-values derived from 16a-Br-E2 (100%)										

FIG. 15